DeepMed Research

Opko Health, Inc.

🇨🇱Chile

Country: 🇨🇱Chile

Ownership: Public

Established: 2005-01-01

Employees: 3.9K

Market Cap: -

Website: http://www.opko.com

Clinical Trials

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

Phase 3

Terminated

Conditions: Chronic Kidney Disease stage3
Chronic Kidney Disease stage4
Vitamin d Deficiency
Secondary Hyperparathyroidism

Interventions: Drug: Placebo
Drug: CTAP101

First Posted Date: 2022-09-16

Last Posted Date: 2024-07-25

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 2

Registration Number: NCT05543928

Locations: 🇺🇸
Nationwide Childrens Hospital, Columbus, Ohio, United States

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Phase 2

Completed

Conditions: Coronavirus
SARS-CoV2 Infection
COVID-19

Interventions: Drug: Rayaldee
Drug: Placebo

First Posted Date: 2020-09-16

Last Posted Date: 2024-05-28

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 171

Registration Number: NCT04551911

Locations: 🇺🇸
OPKO Investigative Site, Omaha, Nebraska, United States

4Kscore Using Serum Stored Uncentrifuged

Completed

Conditions: Prostate Cancer

First Posted Date: 2019-10-17

Last Posted Date: 2019-10-17

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 64

Registration Number: NCT04130776

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

Not Applicable

Completed

Conditions: Cataract
Dry Eye Syndromes

Interventions: Device: Vis Glyc Neo
Device: Physiological saline solution

First Posted Date: 2019-08-21

Last Posted Date: 2021-03-23

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 100

Registration Number: NCT04063644

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Phase 3

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: Genotropin
Drug: MOD-4023

First Posted Date: 2019-03-14

Last Posted Date: 2021-08-12

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 44

Registration Number: NCT03874013

Locations: 🇯🇵
Fukuyama City Hospital, Fukuyama, Hiroshima, Japan
🇯🇵
Hospital of the University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
🇯🇵
National Hospital Organization Kure Medical Center & Chugoku Cancer Center, Kure, Hiroshima, Japan

and more 43 locations

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: Somatrogon

First Posted Date: 2019-01-22

Last Posted Date: 2020-04-28

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 49

Registration Number: NCT03810664

Locations: 🇺🇸
QPS Miami Research Associates, Miami, Florida, United States

Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.

Not Applicable

Completed

Conditions: Osteoarthritis, Knee

Interventions: Device: ENKO 1
Device: Durolane

First Posted Date: 2018-12-03

Last Posted Date: 2021-03-23

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 175

Registration Number: NCT03762408

Locations: 🇪🇸
Clínica ISMEC, Sevilla, Spain
🇪🇸
Consell calatà de l'Esport, Esplugues De Llobregat, Barcelona, Spain
🇪🇸
Clínica Novo Sancti Petri, Chiclana de la Frontera, Cádiz, Spain

and more 15 locations

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

Phase 1

Completed

Conditions: Vitamin D Insufficiency
Secondary Hyperparathyroidism

Interventions: Drug: CTAP101 Capsules

First Posted Date: 2018-09-07

Last Posted Date: 2019-09-30

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 67

Registration Number: NCT03660800

Locations: 🇺🇸
WCCT Global, Inc., Cypress, California, United States

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

Phase 2

Terminated

Conditions: Chronic Kidney Diseases
Secondary Hyperparathyroidism Due to Renal Causes
Stage 5 Chronic Kidney Disease
Vitamin D Deficiency

Interventions: Drug: Calcifediol Oral Capsule
Drug: Placebo oral capsule

First Posted Date: 2018-07-26

Last Posted Date: 2025-03-30

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 44

Registration Number: NCT03602261

Locations: 🇺🇸
Research by Design, LLC, Chicago, Illinois, United States
🇺🇸
Northshore University Health, Evanston, Illinois, United States
🇺🇸
Southwest Houston Research LTD, Houston, Texas, United States

and more 12 locations

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism Due to Renal Causes
Vitamin D Insufficiency
CKD Stage 3
CKD Stage 4

Interventions: Drug: Calcifediol Oral Product
Drug: Cholecalciferol
Drug: Calcifediol Oral Capsule
Drug: Paricalcitol Oral Capsule

First Posted Date: 2018-07-17

Last Posted Date: 2022-12-09

Lead Sponsor: OPKO Health, Inc.

Target Recruit Count: 69

Registration Number: NCT03588884

Locations: 🇺🇸
Research by Design, LLC, Chicago, Illinois, United States
🇺🇸
National Institute of Clinical Research, Inc., Garden Grove, California, United States
🇺🇸
Spaulding Clinical Research, West Bend, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy